A PYMNTS Company

EU: Commission sets deadline for Novartis/Glaxo decision

By  |  December 1, 2014

The European Commission announced Monday that it will decide by January 14 whether to approve Swiss pharmaceutical conglomerate Novartis’s plans to merge with UK rival GlaxoSmithKline.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Novartis is set to acquire Glaxo’s oncology product unit in a $14.5 billion acquisition; an additional $1.5 billion would be paid pending results of an ongoing melanoma treatment trial, reports say.

    Glaxo, meanwhile, would acquire Novartis’s vaccines operations, without the flu vaccine, for $5.25 billion, as well as potential royalties and milestone payments of up to $1.8 billion.

    The Commission is investigating the terms of the transaction and will rule next month on the deal. The announcement comes days after the Commission approved of medical device maker Medtronic’s acquisition of Covidien for $43 billion, though regulators implemented concessions on the deal.

    Full content: Today Online

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.